Novo Nordisk’s Victoza launched in UK under expanded label

Novo Nordisk has announced that its type 2 diabetes therapy Victoza is now available in the UK under an expanded European label.

The European Commission has approved an expansion to the Victoza label which reflects the importance of improving both blood glucose and cardiovascular events as integral elements of type 2 diabetes treatment.

Victoza has demonstrated in the landmark LEADER trial that it is the first and only GLP-1 receptor agonist shown to reduce the risk of cardiovascular events, in addition to lowering blood sugar and reducing weight, in adults with type 2 diabetes.

It is established that people with type 2 diabetes are two to four times more likely to develop cardiovascular disease than the general population, making this the most costly complication of diabetes.

Professor Steve Bain, who led the UK branch of the LEADER trial, said: "We have an option that is proven to be effective not only in lowering blood sugar levels and reducing weight, but in improving the cardiovascular outcomes of our patients with diabetes that are at such increased risk."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.